{"disease":{"id":"hiv-1","name":"hiv 1"},"drugs":{"marketed":[{"drug_id":"lenacapavir","indication_name":"Multidrug resistant HIV-1 infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunlenca","generic_name":"LENACAPAVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":58,"revenue":"1600","mechanism":"Sunlenca works by binding to a specific site on the HIV-1 protease, preventing the virus from replicating."},{"drug_id":"zidovudine","indication_name":"HIV-1 Infection Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retrovir","generic_name":"ZIDOVUDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Thymidine kinase, cytosolic","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Retrovir works by mimicking the natural building blocks of DNA to prevent HIV from replicating."},{"drug_id":"lopinavir","indication_name":"HIV-1 Infection Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kaletra","generic_name":"LOPINAVIR","company_name":"Abbvie Deutschland Gmbh Co. Kg","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Kaletra blocks the protease enzyme, preventing the HIV virus from replicating."},{"drug_id":"tenofovir-disoproxil-fumarate","indication_name":"HIV-1 Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TENOFOVIR DISOPROXIL FUMARATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":34,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl163","indication_name":"HIV-1 Infection Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RITONAVIR","company_name":"","drug_phase":"marketed","molecular_target":"CYP3A","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Lopinavir and ritonavir tablets increase lopinavir plasma levels by inhibiting its CYP3A-mediated metabolism."},{"drug_id":"atazanavir-sulfate","indication_name":"HIV-1 Infection Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ATAZANAVIR SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"riv","indication_name":"HIV-1 infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."},{"drug_id":"elvitegravir","indication_name":"Treatment of HIV-1 Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitekta","generic_name":"ELVITEGRAVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Vitekta blocks the integrase enzyme, preventing HIV from replicating."},{"drug_id":"part-b-multiple-dose-atm-avi-cohorts-1-4","indication_name":"Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options or for whom it is not feasible to use antiretroviral therapy in certain resource-limited settings","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part B: Multiple-dose ATM-AVI, Cohorts 1-4","generic_name":"part-b-multiple-dose-atm-avi-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1","drug_class":"Antiretroviral","quality_score":37,"revenue":null,"mechanism":"The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified."}],"pipeline":[],"offLabel":[],"totalMarketed":72,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04605354","title":"Epidemiological and Clinical Description of Women Living With HIV in Selected Countries of Latin America","phase":"","overall_status":"UNKNOWN","enrollment_count":25816,"lead_sponsor_name":"Helios Salud","has_results":false},{"nct_id":"NCT00552214","title":"Evaluation of HIV-1, HCV and HBV Blood Screening Tests With Human Blood Donor Specimens","phase":"NA","overall_status":"COMPLETED","enrollment_count":10290,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT06492187","title":"Triage Survey for Infectious Disease Eligibility","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brooklyn Clinical Research","has_results":false},{"nct_id":"NCT03101592","title":"INTERVAL: Varying Intervals of ART to Improve Outcomes in HIV","phase":"NA","overall_status":"TERMINATED","enrollment_count":9118,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT01078246","title":"Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)","phase":"","overall_status":"COMPLETED","enrollment_count":7124,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01078233","title":"Observational Data Analysis in EuroSIDA (MK-0518-058)","phase":"","overall_status":"COMPLETED","enrollment_count":6617,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05405582","title":"Thetha Nami Ngithethe Nawe (\"Let's Talk\"): Step Wedge cRCT of Peer Led Community PrEP and SRH for Youth in South Africa","phase":"NA","overall_status":"UNKNOWN","enrollment_count":6000,"lead_sponsor_name":"Africa Health Research Institute","has_results":false},{"nct_id":"NCT06900829","title":"#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.","phase":"NA","overall_status":"RECRUITING","enrollment_count":5200,"lead_sponsor_name":"Casper Rokx","has_results":false},{"nct_id":"NCT07186244","title":"Prevention ICONA Dedicated Ensemble","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Fondazione ICONA","has_results":false},{"nct_id":"NCT03052010","title":"The Partners Scale-Up Project","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":4898,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT04513496","title":"Telemedicine in HIV Care in Buenos Aires","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Fundacion Ibis","has_results":false},{"nct_id":"NCT03866759","title":"Prospective Observational Cohort HIV & STI Study in Europe","phase":"","overall_status":"COMPLETED","enrollment_count":3593,"lead_sponsor_name":"Hendrik Streeck","has_results":false},{"nct_id":"NCT07021092","title":"PERSON-CENTERED APPROACHES TO VIREMIA: CONNECTION, RAPPORT, AND ENGAGEMENT STUDY","phase":"NA","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Centre for Infectious Disease Research in Zambia","has_results":false},{"nct_id":"NCT03060629","title":"A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2636,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT05481216","title":"HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV","phase":"","overall_status":"COMPLETED","enrollment_count":2598,"lead_sponsor_name":"NEAT ID Foundation","has_results":true},{"nct_id":"NCT05652400","title":"HIV Transmission in the Era of Scaling up Antiretroviral Therapy in Ethiopia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Lund University","has_results":false},{"nct_id":"NCT03706950","title":"Post-approval Observational Study of Elpida® in the First Line Therapy for HIV-1 Infected Patients With Background Standard ART","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Viriom","has_results":false},{"nct_id":"NCT04061889","title":"Clinical Epidemiology Cohort Study for Patient Living With HIV","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Kaohsiung Veterans General Hospital.","has_results":false},{"nct_id":"NCT04776252","title":"Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03183154","title":"Mathematical Modeling of the HIV Transmission Risk After Initiation of Antiretroviral Therapy in naïve HIV-infected","phase":"","overall_status":"UNKNOWN","enrollment_count":1831,"lead_sponsor_name":"Hospital General Universitario Gregorio Marañon","has_results":false},{"nct_id":"NCT03870438","title":"Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1506,"lead_sponsor_name":"ANRS, Emerging Infectious Diseases","has_results":false},{"nct_id":"NCT04238767","title":"Dolutegravir in Real Life in Lesotho","phase":"","overall_status":"COMPLETED","enrollment_count":1433,"lead_sponsor_name":"Swiss Tropical & Public Health Institute","has_results":false},{"nct_id":"NCT03500172","title":"HIV Treatment Retention Interventions for Women Living With HIV (Siyaphambili Study)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1391,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":true},{"nct_id":"NCT04050449","title":"Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD","phase":"","overall_status":"COMPLETED","enrollment_count":1339,"lead_sponsor_name":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","has_results":false},{"nct_id":"NCT04738812","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1330,"lead_sponsor_name":"ANRS, Emerging Infectious Diseases","has_results":false},{"nct_id":"NCT06637813","title":"Establishment of a Database of HIV Subjects Initiating or Simplifying Dual Therapy With Dolutegravir/Lamivudine","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1220,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT07293559","title":"Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States","phase":"","overall_status":"RECRUITING","enrollment_count":1150,"lead_sponsor_name":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","has_results":false},{"nct_id":"NCT03122262","title":"ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1110,"lead_sponsor_name":"Professor Francois Venter","has_results":false},{"nct_id":"NCT04066036","title":"Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02345226","title":"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":881,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT06393387","title":"Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Midway Specialty Care Center","has_results":false},{"nct_id":"NCT03297216","title":"Improving Pregnancy Outcomes With Progesterone","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":true},{"nct_id":"NCT04229290","title":"Second-line Switch to Dolutegravir Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":795,"lead_sponsor_name":"University of Nairobi","has_results":false},{"nct_id":"NCT03593629","title":"Kenya HIV Self-Testing in PrEP Delivery","phase":"NA","overall_status":"COMPLETED","enrollment_count":790,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT02275780","title":"Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":769,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04568239","title":"Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)","phase":"","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"Association de Recherche en Virologie et Dermatologie","has_results":false},{"nct_id":"NCT04255849","title":"Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":700,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT05374109","title":"SYV: A Mental Health Intervention to Improve HIV Outcomes in Tanzanian Youth","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":690,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT03360422","title":"ANCHORS Study: UH2 Project","phase":"NA","overall_status":"COMPLETED","enrollment_count":673,"lead_sponsor_name":"University of Florida","has_results":true},{"nct_id":"NCT02397096","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":673,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02121795","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":668,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02607956","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":657,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02345252","title":"Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":632,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03194477","title":"Providing Unique Support for Health (PUSH) Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":631,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT05998499","title":"HIV-Infected Latin American Asylum Seekers in Europe: Insights From the EuroLatin HIV Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":631,"lead_sponsor_name":"Hospital Universitario Infanta Leonor","has_results":false},{"nct_id":"NCT02607930","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":631,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05067400","title":"SARS-CoV-2 (COVID-19) Antibody PrevalencE in an Adult London HIV Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"Royal Free Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT03070223","title":"PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":602,"lead_sponsor_name":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","has_results":true},{"nct_id":"NCT05924438","title":"A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Professor Francois Venter","has_results":false},{"nct_id":"NCT04233879","title":"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":599,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}